战略剥离和财务灵活性:HLS Therapeutics Inc买入评级乐观
Stifel Nicolaus保持对HLS Therapeutics Inc(HLS)的持有评级。
出于收入考虑,HLS Therapeutics将评级下调至Stifel GMP持平;目标股价下调至5.00加元
HLS Therapeutics Inc(HLS)获得 Stifel Nicolaus 的收购
Bloom Burton 获得买入评级 HLS Therapeutics Inc (HLS)
Clarus 坚持其对 HLS Therapeutics Inc (HLS) 的买入评级
HLS Therapeutics Inc (HLS) 获得 Stifel Nicolaus 的买入评级
Stifel Nicolaus 仍然买入 HLS Therapeutics Inc (HLS)
Stifel Nicolaus 维持对 HLS Therapeutics Inc(HLS)的买入评级
Stifel Nicolaus 维持对 HLS Therapeutics Inc(HLS)的买入评级
HLS Therapeutics Inc (HLS) 获得 Clarus 的买入评级
HLS Therapeutics Inc(HLS)获得 Stifel Nicolaus 的收购